Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Progression -188% Improvement Relative Risk c19early.org/n ANTICOV et al. NCT04920838 ANTICOV Nitazoxanide RCT EARLY Is early treatment with nitazoxanide+ciclesonide beneficial for COVID-19? RCT 905 patients in multiple countries Trial compares with paracetamol, results vs. placebo may differ Higher progression with nitazoxanide+ciclesonide (p=0.04) ANTICOV News Favors nitazoxanide Favors paracetamol
ANTICOV Trial Finds Nitazoxanide/Ciclesonide Drug Combination Does Not Reduce Hospitalisation Risk in Patients With Mild COVID-19
ANTICOV News (News), ANTICOV, NCT04920838 (history)
ANTICOV, ANTICOV Trial Finds Nitazoxanide/Ciclesonide Drug Combination Does Not Reduce Hospitalisation Risk in Patients.., News (News), ANTICOV, NCT04920838
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT with 462 nitazoxanide/ciclesonide and 443 paracetamol patients, up to 7 days from onset, showing no significant difference in progression. Minimal details, with the primary mortality outcome and treatment delay not being reported. This study is excluded in the after exclusion results of meta analysis: minimal details provided.
risk of progression, 187.7% higher, RR 2.88, p = 0.04, treatment 15 of 462 (3.2%), control 5 of 443 (1.1%), SpO2 ≤ 93% within 14 days.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
ANTICOV et al., 28 Feb 2022, Randomized Controlled Trial, multiple countries, preprint, 1 author, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with ciclesonide) - results of individual treatments may vary, trial NCT04920838 (history) (ANTICOV).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperNitazoxanideAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit